Akatinib/Acalatinib: why should it be used with caution?

Acalabrutinib/Acalabrutinib, a leader among second-generation BTK inhibitors, has shown significant efficacy in the treatment of hematological malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia, especially for adult patients who have already experienced one chemotherapy drug. Its core mechanism is to effectively curb the proliferation of cancer cells.

Clinical studies have shown that common side effects in patients taking acotinib include diarrhea, headache, upper respiratory tract infection, joint pain, and bruising. Although these side effects will gradually subside over the course of treatment in most cases, patients may still encounter more serious health problems, such as bleeding, infection, arrhythmia, etc. These problems will undoubtedly affect the patient's daily life and may even interfere with the effectiveness of the treatment.

In addition, acotinib is not suitable for everyone. For example, patients who are allergic to acotinib or similar drugs should strictly avoid using this drug. At the same time, patients with severe heart disease, bleeding tendency or liver function impairment also need to consult a doctor. These contraindications require some patients to be extra cautious when choosing treatment options.

In addition to the above contraindications, patients should also avoid ingesting grapefruit-related products during medication, because grapefruit will inhibitCYP3A metabolism, which may increase the concentration of acotinib in the serum, thereby affecting the efficacy and safety of the drug. If combined use is necessary, the drug dosage may need to be adjusted. At the same time, patients should also use St. John's wort with caution. This herb may reduce the serum level of acotinib and interfere with the therapeutic effect. In addition, patients taking antacids should note that the time between taking antacids and acotinib should be at least 2 hours apart to avoid drug-drug interactions.